Hansa Biopharma AB (publ) (HNSA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Hansa Biopharma first quarter 2026 earnings results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone telephone. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Hansa Biopharma CEO, Renée Aguiar-Lucander. Please go ahead. Thank you very much. Good afternoon. Good morning, everybody. And welcome to the Hansa Biopharma conference call to review the Q1 results for 2026. I'm Renee Aguilar-Lukander, CEO for HANSA Biopharma. And joining me today is Evan Ballantyne, Chief Financial Officer, Richard Phillipson, Chief Medical Officer, and Maria Thornson, Chief Operating Officer and President of the U.S. Please, next slide, please. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during the presentation. You should therefore apply appropriate caution. Next slide, please. This is the agenda for today's call. And these are the people who will, as I just mentioned, who will be covering the different sections. Next slide, please. So let me start by taking you through an overview of the quarter. As I mentioned in the Q4 report, we expected Q1 to be impacted by the significant number of initiatives which we rolled out during the quarter, which I'll cover in some more detail later in the presentation. This is intended also that what, This is indeed also will be observed, with revenues amounting to 34.6 million Swedish crowns, slightly above Q3 of 2025. We...